Travere therapeutics reports fourth quarter and full year 2022 financial results

Recently received u.s. fda accelerated approval of filspari™ (sparsentan), the first and only non-immunosuppressive therapy for the reduction of proteinuria in iga nephropathy (igan)

TVTX Ratings Summary

TVTX Quant Ranking